OR WAIT null SECS
Merck Millipore’s collaboration with celares GmbH launches pegylation services for protein-based therapeutics.
Merck Millipore, the life science business of Merck, announced a collaboration with celares GmbH to provide pegylation services to customers developing protein-based therapeutics and biosimilars. The service includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities for pilot and subsequent commercial scale.
The services will leverage EMD Millipore’s functionalized PEG products of different molecular weight and activation chemistry, buffers, solvents and excipients, and unit operations employed during the pegylation process and subsequent purification including tangential and normal flow filtration and chromatography.
Source: Merck Millipore